JOHNSON & JOHNSON

Johnson & Johnson’s Phase 3 results for ICOTYDE® show sustained clearance in difficult‑to‑treat scalp, genital and hand/foot psoriasis with no new safety signals, promising a durable, cost‑effective IL‑23 peptide therapy.

Johnson & Johnson Q3 earnings reveal steady revenue growth, robust R&D spend, and a strategic push into oncology, while highlighting risks from regulatory pressure and fierce competition.

Johnson & Johnson’s IMAAVY shows sustained 2‑year control of generalized myasthenia gravis with a steroid‑sparing effect, offering high‑value benefit to patients, clinicians and payers.

J&J’s new clinical wins for TREMFYA® in axial‑PsA and CARVYKTI® in early‑line myeloma boost its leadership in biologics and CAR‑T therapy, reshaping market dynamics.

Johnson & Johnson’s steady stock, strong margins, and cutting‑edge digital health strategy position it to thrive as healthcare shifts toward value‑based care.

Explore J&J’s new COPERNICUS lung‑cancer data: SC dosing, lower AEs, and potential market edge—can it boost revenue and payer value?

Johnson & Johnson’s subcutaneous RYBREVANT FASPRO + LAZCLUZE combo shows far lower adverse events and VTE in EGFR‑mutated NSCLC, promising better patient safety, compliance and cost‑effective care.

Johnson & Johnson’s final PAPILLON trial data reveal RYBREVANT gives the longest overall survival for advanced NSCLC patients with EGFR exon 20 insertion mutations—36 months versus 24 months with chemo alone.

J&J’s De Puy Synthes spin‑off: a $20 bn move that reshapes orthopaedics, unlocks capital, and could shift pricing, reimbursement, and patient access.

J&J launches a CE‑marked 2‑week reusable contact lens with proven safety, comfort and UV protection, while its stock remains steady and governance stays transparent.